The need for health data in the era of Covid-19 (October 2020)

The Covid-19 pandemic underscores the need for high-quality health data that is readily deployed. Europe’s early epidemiological assessments at the start of the pandemic projected infection and mortality rates by orders of magnitude in error. Once the pandemic was in full swing, official statistics in most European countries underreported coronavirus-related deaths. More recently, the retraction of two separate clinical studies for hydroxychloroquine published in two top medical journals due to unreliable primary data collection and meta-analysis demonstrated the importance of data quality for assessing vitally needed medicines. This session will offer distinct perspectives on how to address data problems such as these in the future so as to steer health policy with clarity and minimize negative repercussions on health outcomes beyond the pandemic.

Determining value for patients and harnessing RWE (October 2020)

With the growing use of regulatory tools such as conditional approvals and breakthrough designations, the traditional bottleneck of regulatory approval is today seen as far less problematic than it was previously. However, the early assessment of new products is also increasingly accompanied by smaller datasets that are often extrapolated for outcomes and survival. This creates enormous challenges for Europe’s HTA bodies, which need to assess these new treatments based on limited quantities of long-term outcomes data. This session will explore how EHDEN can function as a platform to capture longer-term outcomes data and provide alternative reimbursement and assessment approaches to facilitate comparative effectiveness measures.

What could the pharma industry look like by 2030? (October 2020)

Science is leading us down the path of increasingly targeted medicines with accompanying advances in genomics and our ability to develop personalised therapies for patients. However, there are increasing challenges in the development of drugs for ever smaller populations since, by definition, the rarer a disease is, the fewer people there are with the disorder that can participate in clinical research. EHDEN and other GDPR-compliant data-sharing platforms provide an alternative approach to drug development that enables researchers to search millions of historical anonymous patient records to model different scenarios and “health personas”, and to accelerate the development of medicines currently not available to patients in need. This session will provide an overview of RCT-alternative approaches, as well as explore the potential application of machine learning within the clinical trials domain.

Evidence generation for HTA: what role for the OMOP Common Data Model and EHDEN? (January 2020)

Most countries in Europe have formal #health technology assessment processes to inform clinical practice and/or the coverage and reimbursement of new medical technologies. Some bodies focus on the relative effectiveness of technologies, while others additionally assess #cost-effectiveness, i.e. are any additional costs justified by the additional benefits? Because HTA bodies are typically interested in the long-term (usually lifetime) impact of technologies in clinical practice, clinical trials alone are not sufficient to inform decisions, and modelling is often required.
Models are data hungry, usually requiring data on disease prevalence, natural disease history, treatment utilisation, long-term effectiveness and safety, health-related quality of life, and healthcare utilisation. It can be challenging to find and access datasets containing all appropriate data and using multiple datasets requires analysts to be familiar with the structure and coding of each, and to develop separate analysis scripts. As such, the federated data network which EHDEN aims to develop and the OMOP common data model (#OMOP-CDM) and associated tools (through the OHDSI network) have the potential to alleviate some of these challenges. In this webinar, we discuss the uses of HTA, the challenges of evidence generation for HTA, and think about how the OMOP-CDM, #OHDSI tools, and the EHDEN network can support such evidence generation, how these tools and networks could be further developed to better support HTA, and where challenges are likely to remain in the future.

Reducing cancer deaths and complications by leveraging OMOP and OHDSI (September 2019)

Surgery is the major treatment option for #colorectal #cancer, which today is the third most common form of cancer worldwide. However, understanding when and how to apply surgery, in combination with drugs, radiotherapy and other medical treatment options, is an ongoing field of research.

In this webinar, Ismail Gögenur, director of the Center for Surgical Science at Zealand University Hospital in Denmark, will explain how his team is utilising the #OMOP Common Data Model and the #OHDSI tools to achieve a holistic view on the risk profile and treatment options for colorectal cancer patients. While earlier webinars focused on the EHDEN project, the OMOP CDM itself and ways to generate medical #evidence, this one will focus on arguably the most impactful aspect: using OMOP, OHDSI and EHDEN to make better decisions in clinical practice, reducing mortality and complications by the smart use of medical data at scale.

The future of primary care research in Catalonia (July 2019)

In this installment of the EHDEN webinar series, Kees van Bochove invited Talita Duarte Salles and Leonardo Mendez Boo from SIDIAP (www.sidiap.org) to discuss their journey of adopting the OMOP CDM. This webinar discussed SIDIAP's journey and how they benefited from adopting OMOP.

EHDEN - 21st Century Real World Open Science (July 2019)

In this webinar of the EHDEN webinar series, Peter Rijnbeek (Erasmus Medical Center) and Nigel Hughes (Janssen Pharmaceutica) discuss the European Health Data & Evidence Network. They explain the scope and objectives of EHDEN and how they believe EHDEN will transform the way real-world evidence is being generated. Additionally, the open call processes is explained and in particular, how SMEs and data sources can both contribute and benefit from EHDEN.

From question to publication in 5 days (March 2019)

In this 1st webinar of the EHDEN webinar series, Kees van Bochove (TheHyve) and Daniel-Prieto Alhambra (University of Oxford) will discuss the EHDEN and OHDSI Study-a-thon which was organized at the University of Oxford in December 2018. They will explain the concept of this 5-day meeting and how they were able to go from question, to cohort characterization, to data analysis and ultimately to evidence generation in only 5 days.